Cargando…

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings

BACKGROUND AND OBJECTIVE: Baloxavir marboxil, a prodrug that is metabolized to baloxavir acid, suppresses viral replication by inhibiting cap-dependent endonuclease. This first-in-human phase I study evaluated the safety, tolerability, and pharmacokinetics of baloxavir marboxil/baloxavir acid in hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koshimichi, Hiroki, Ishibashi, Toru, Kawaguchi, Nao, Sato, Chisako, Kawasaki, Akira, Wajima, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267547/ https://www.ncbi.nlm.nih.gov/pubmed/30288682 http://dx.doi.org/10.1007/s40261-018-0710-9

Ejemplares similares

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2020)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2019)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals
por: Liu, Yanmei, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
por: Kim, Yun, et al.
Publicado: (2021)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
por: Hansen, Svenn, et al.
Publicado: (2023)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study
por: Yoshino, Yusuke, et al.
Publicado: (2020)

The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)

Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis
por: Seldeslachts, Laura, et al.
Publicado: (2021)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018)

1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
por: Neuberger, Eddie, et al.
Publicado: (2020)

Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil
por: Hashimoto, Takashi, et al.
Publicado: (2020)

Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil
por: Yoshino, Ryunosuke, et al.
Publicado: (2019)

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
por: Nezu, Keiko, et al.
Publicado: (2023)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002
por: Hamza, Hazem, et al.
Publicado: (2021)

Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
por: Komeda, Takuji, et al.
Publicado: (2020)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models
por: Fukao, Keita, et al.
Publicado: (2019)

Baloxavir marboxil: un potente inhibidor de la endonucleasa cap-dependiente de los virus gripales
por: Reina, Jordi, et al.
Publicado: (2019)

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
por: Lou, Yan, et al.
Publicado: (2021)

Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
por: Portsmouth, Simon, et al.
Publicado: (2020)

Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus
por: Baba, Keiko, et al.
Publicado: (2020)

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
por: Baker, Jeffery B., et al.
Publicado: (2023)

Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database( )
por: Miyazawa, Shogo, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
por: Kawaguchi, Nao, et al.
Publicado: (2021)

2644. Evaluation of Clinical Course and Heath-Related Quality-of-Life Following Treatment with Oseltamivir, Laninamivir, and Baloxavir Marboxil in Adult Patients with Seasonal Influenza: Prospective Observational Study
por: Yoshino, Yusuke, et al.
Publicado: (2019)

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_02epf06imcrlb7eeqc5fo6p5mb